Sagimet Biosciences Inc. Series A Common Stock (SGMT NASDAQ) stock market data APIs
$8.2456
-0.25(-3%)
as of July 3, 2025
Try our APIs with
free plan!
Sagimet Biosciences Inc. Series A Common Stock Financial Data Overview
Price chart is built with
Anychart
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Prev. Close
8.2456
Open
7.9978
High
8.4296
Low
7.8066
52 wk Range
1.73-10.425
Market Cap
261 M
Shares Outstanding
30 675 K
EPS
-0.56
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Sagimet Biosciences Inc. Series A Common Stock data using free add-ons & libraries
Get Sagimet Biosciences Inc. Series A Common Stock Fundamental Data
Sagimet Biosciences Inc. Series A Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Sagimet Biosciences Inc. Series A Common Stock Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: 2025-05-08
- EPS/Forecast: -0.71
Get Sagimet Biosciences Inc. Series A Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sagimet Biosciences Inc. Series A Common Stock News
New
Sagimet stock holds steady as JMP reiterates $31 price target
JMP Securities reiterated its Market Outperform rating and $31.00 price target on Sagimet Biosciences Inc (NASDAQ:SGMT), currently trading at $7.40, following positive Phase 3 acne data from the com...
Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025
SAN MATEO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabo...
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks were higher late Wednesday afternoon, with the NYSE Health Care Index up 0.6% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Sagimet climbs as acne therapy hits main goals in late-stage trial in China
[acne skin layer, Skin treatments , cosmetology and skincare problems. 3d rendering.] anusorn nakdee/iStock via Getty Images Sagimet Biosciences (NASDAQ:SGMT [https://seekingalpha.com/symbol/SGMT]) a...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
